Korean biotech firm Alteogen Inc. has publicized the findings of their most recent Tergase® clinical study, wherein no occurrence of ADA (inclusive of neutralizing antibodies) was found.

Arcturus Therapeutics Holdings have revealed today that EMA has officially confirmed the marketing authorization application for ARCT-154.

the Italfarmaco Group  has publicly declared that they have submitted a Marketing Authorization Application for Givinostat.

Stoke Therapeutics, Inc., reported today key points from presentations pertaining to the continued clinical research of STK-001.

ILiAD Biotechnologies, LLC, a biotech firm in the clinical trial phase, which is spearheading the creation of an unparalleled, progressive pertussis vaccine, reports promising preliminary results from the CHAMPION-1 clinical trial.

Novo Nordisk is vigorously pursuing the rollout of the obesity medication, Wegovy, across Europe, despite grappling with supply chain issues.

Zenas BioPharma disclosed today their signing of a licensing and partnership contract with Bristol Myers Squibb Company.

Genmab A/S and Seagen Inc.  revealed that its main objective of overall survival when TIVDAK®(tisotumab vedotin-tftv) was used in comparison to chemotherapy only.

The multinational healthcare firm, Viatris Inc., has shared news of the tentative approval from FDA)for an abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg oral suspension tablet New Drug Application .

Swedish precision oncology firm, Beactica Therapeutics AB, has today unveiled BEA-17 as their chosen preclinical candidate within the LSD1 initiative

ACM Biolabs has revealed encouraging preliminary findings from a Phase I evaluation of ACM-001, their inaugural clinical-stage development initiative.

InvIOs GmbH revealed today that it has launched patient enrollment for a Phase 1b trial of its innovative autologous cell therapy, APN401, focusing on solid tumor patients.